Free Trial

Eledon Pharmaceuticals 11/12/2024 Earnings Report

Eledon Pharmaceuticals logo
$4.36 +0.14 (+3.32%)
(As of 12/20/2024 05:16 PM ET)

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Wall Street Icon: “You must get on the right side of this thing” (Ad)

I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.

This market shakeup is going to be much more intense.

Eledon Pharmaceuticals Earnings Headlines

⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Eledon Pharmaceuticals Reports Strong Q3 2024 Results
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

View Eledon Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings